Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena

Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

05-Sep-2005

Anika Therapeutics, Inc. announced that it has reached a mutual agreement with OrthoNeutrogena, a division of Ortho-McNeil Pharmaceuticals, for the termination of its development and commercialization contract for Anika's hyaluronic acid based cosmetic tissue augmentation (CTA) product, effective August 31, 2005.

In related news, Anika also announced that, subsequent to such termination, it has filed a pre-market approval application (PMA) with the U.S. Food and Drug Administration for its CTA product and is currently exploring options for its worldwide commercialization.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances